Rofuclav 500/125

Indications of Rofuclav 500/125 Tablet

Rofuclav 500/125 Tablet is indicated for the treatment of infections caused by sensitive bacteria. Pharingitis / Tonsilite caused by Pyogenes Streptococcus.

• Acute Bacterial Otite Caused by Streptococcus Pneumoniae, Haemophilus Influenzae, Moraxella Catarris (Beatalactamase Producing Logs) or Streptococcus Pyogenes.
• Acute bacterial maxillary sinuses caused by Streptococcus pneumonia or Hemophilus influenza (non-beta-lactamase production strains)
• Infections of the lower respiratory tract, including pneumonia, caused by streptococcus pneumonia, Haemophilus influenza (including beta lactamase production logs), Klebsiella spp., Staphylococcocco Aureus. (Penicillinasi and non-penicillin production strains), Streptococcus Pyogenes, E. coli.
• Acute bacterial exacerbation of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by pneumonia streptococci, flu hemophile (negative Beatamasi strains) or Haemophilus paraininfluzee (beta-lactamase negative strains).
• Uncomplicated skin infections and skin structure caused by Staphylococcus aureus (including beta-lactamase production strains) or streptococcus pyogenes.
• urinary tract infections without complications caused by E.coli or Klebsiella pneumonia.
• bone and articular infections caused by Staphylococcus aureus (penicillinase and non-penicillinase strains).
• Gonorrhea without complications caused by penicillin production and stumps that produce the non-penicillinase of Neisseria Gororroae.
• Initial Lyme disease (migrant erythema) caused by Borrelia burgdorferi.
• Septicemia caused by Staphylococcus aureus, Streptococcus pneumonia, E.coli, Haemophilus influenzae (including ampsick strains), and Klebsiella spp.
• meningitis caused by streptococcus pneumonia, Haemophilus influenza (including ampsick strains), Neisseria meningitidis & staphylococcus aureus (penicillinases and non-penicillinase production of production strains) switching therapy
• (injectable to oral)

Pharmacology of Rofuclav 500/125 Tablet

Cefuroxime is a bactericidal second-generation cephalosporin antibiotic that kills a wide spectrum of Gram-positive and Gram-negative bacteria, including many beta-lactamase-producing strains. Cefuroxime works by interfering with the transpeptidation process, which stops bacteria from making cell walls.

Streptomyces clavuligerus produces clavulanic acid, a naturally derived beta-lactamase inhibitor. It has a structure comparable to beta-lactam antibiotics, and it binds to beta-lactamase enzymes and inactivates them irreversibly. Clavulanic acid protects Cefuroxime against breakdown by beta-lactamase enzymes, making it a viable therapy option for bacterial infections.

Rofuclav 500/125 Tablet Dosage & Administration

Adolescents and adults (13 years and older)-

• Pharyngitis/tonsillitis: 250 mg b.i.d. for 5-10 days
• Acute bacterial maxillary sinusitis: 250 mg b.i.d. for 10 days
• Acute bacterial exacerbation of chronic bronchitis: 250-500 mg b.i.d. for 10 days
• Secondary bacterial infections of acute bronchitis: 250-500 mg b.i.d. for 5-10 days 
• Uncomplicated skin and skin structure infections: 250-500 mg b.i.d. for 10 days
• Uncomplicated urinary tract infections: 250 mg b.i.d. for 7-10 days
• Uncomplicated Gonorrhoea: 1000 mg b.i.d. Single dose
• Community acquired pneumonia: 250-500 mg b.i.d. for 5-10 days
• MDR Typhoid Fever: 500 mg b.i.d. for 10-14 days
• Early Lyme disease: 500 mg b.i.d. for 20 days

Paediatric Patients (3 months to 12 years)-

• Pharyngitis/Tonsillitis: 20 mg/kg/day b.i.d for 5-10 days
• Acute otitis media: 30 mg/kg/day b.i.d for 10 days
• Acute bacterial maxillary sinusitis: 30 mg/kg/day b.i.d for 10 days
• Impetigo: 30 mg/kg/day b.i.d for 10 days

The cefuroxime-Clavulanic Acid tablet may be taken without regard to food.

Interaction

The area under the serum concentration versus time curve increases by 50% when probenecid and Cefuroxime-Clavulanic Acid are given together. A drug that lowers stomach acidity may impair Cefuroxime bioavailability and neutralize the impact of postprandial absorption.

Contraindications

Cefuroxime-Clavulanic Acid is not recommended for people who have a known cephalosporin allergy or who have Pseudomembranous Colitis.

Rofuclav 500/125 Tablet Side Effects

Cefuroxime-Clavulanic Acid is generally well tolerated. However, nausea, vomiting, diarrhea, abdominal discomfort, or pain are possible adverse effects. Prolonged use of Cefuroxime and Clavulanic acid together, like other broad-spectrum antibiotics, can lead to nonsusceptible microorganism overgrowth. Renal failure, anaphylaxis, angioedema, pruritis, rash, and serum sickness, such as urticaria, can occur in a small percentage of patients (0.2 percent).

Pregnancy & Lactation

Antibiotics should be avoided if at all possible throughout the first trimester. Cefuroxime-Clavulanic Acid, on the other hand, can be safely used to treat urinary and other infections later in pregnancy. Cefuroxime-Clavulanic Acid is excreted in modest amounts in breast milk. However, the possibility of the newborn being sensitized should be considered.

Precautions & Warnings

Cefuroxime should be used with caution in individuals who are taking powerful diuretics and have a history of colitis.

Therapeutic Class

Second generation Cephalosporins

Storage Conditions

Store in a cool, dry place (below 30o C), away from light and moisture. Keep out of the reach of children.

Pharmaceutical Name of Rofuclav 500/125 Tablet

Radiant Pharmaceuticals Limited

Generic

Cefuroxime Axetil + Clavulanic Acid